NASDAQ:PRQR

ProQR Therapeutics - PRQR Stock Forecast, Price & News

$0.88

+0.05 (+6.06%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.80
▼
$0.88
50-Day Range: $0.74
▼
$0.89
52-Week Range: $0.53
▼
$8.67

Volume: 1.75 million shs
Average Volume: 1.03 million shs
Market Capitalization: $62.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 471.4% Upside
$5.00 Price Target
Short Interest: Healthy
0.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.81) to ($0.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

684th out of 1,072 stocks

Pharmaceutical Preparations Industry

326th out of 534 stocks

3.3

Analyst's Opinion

Consensus Rating
ProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, ProQR Therapeutics has a forecasted upside of 471.4% from its current price of $0.88.
Amount of Analyst Coverage
ProQR Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.61% of the float of ProQR Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
ProQR Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ProQR Therapeutics has recently increased by 1.66%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ProQR Therapeutics does not currently pay a dividend.
Dividend Growth
ProQR Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRQR.

2.7

News and Social Media Coverage

News Sentiment
ProQR Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for ProQR Therapeutics this week, compared to 1 article on an average week.
Search Interest
5 people have searched for PRQR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 31.07% of the stock of ProQR Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ProQR Therapeutics are expected to grow in the coming year, from ($0.81) to ($0.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ProQR Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProQR Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ProQR Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Stock News Headlines

September 29, 2022 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) Receives $5.80 Average PT from Analysts

September 6, 2022 | reuters.com

ProQR Therapeutics NV

August 12, 2022 | finance.yahoo.com

Raymond James Bullish On This Penny Stock's Reprioritized Pipeline

August 12, 2022 | seekingalpha.com

ProQR upgraded at Raymond James on RNA-editing platform

August 11, 2022 | finance.yahoo.com

This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing

August 11, 2022 | seekingalpha.com

ProQR says EU regulator seeks additional trial for lead candidate

August 11, 2022 | finance.yahoo.com

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

August 4, 2022 | finance.yahoo.com

ProQR Announces Second Quarter 2022 Operating and Financial Results

July 8, 2022 | finance.yahoo.com

Investors in ProQR Therapeutics (NASDAQ:PRQR) have unfortunately lost 90% over the last three years

June 28, 2022 | finance.yahoo.com

ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

June 1, 2022 | finance.yahoo.com

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

May 9, 2022 | finance.yahoo.com

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

May 6, 2022 | markets.businessinsider.com

Expert Ratings for ProQR Therapeutics

May 5, 2022 | finance.yahoo.com

ProQR (PRQR) Reports Q1 Loss, Tops Revenue Estimates

May 5, 2022 | finance.yahoo.com

ProQR Announces First Quarter 2022 Operating and Financial Results

May 3, 2022 | finance.yahoo.com

Bears are Losing Control Over ProQR (PRQR), Here's Why It's a 'Buy' Now

April 28, 2022 | finance.yahoo.com

ProQR (PRQR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

April 19, 2022 | finance.yahoo.com

ProQR to Participate in the Kempen Life Sciences Conference

April 13, 2022 | finance.yahoo.com

ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce

April 13, 2022 | msn.com

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

April 13, 2022 | finance.yahoo.com

ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

April 4, 2022 | finance.yahoo.com

ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

March 23, 2022 | finance.yahoo.com

ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

February 24, 2022 | finance.yahoo.com

ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates

February 24, 2022 | finance.yahoo.com

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings: 8/04/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRQR
CUSIP: N/A
CIK: 1612940
Web: www.proqr.com
Phone: (188) 166-7000
Fax: N/A
Employees: 1,504
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +471.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,900,000.00
Net Margins: -1,859.05%
Pretax Margin: -1,866.41%
Return on Equity: -57.34%
Return on Assets: -31.84%

Debt

Debt-to-Equity Ratio: 0.43
Current Ratio: 5.93
Quick Ratio: 5.93

Sales & Book Value

Annual Sales: $1.60 million
Price / Sales: 38.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.88 per share
Price / Book: 0.47

Miscellaneous

Outstanding Shares: 71,291,000
Free Float: N/A
Market Cap: $62.38 million
Optionable: Optionable
Beta: 0.81

Key Executives

Dr. Domenico Valerio Ph.D. (Age 66)
Founder & Independent Chairman of Supervisory Board
Comp: $70.2k

Mr. Daniel Anton de Boer (Age 39)
Founder, CEO & Member of Management Board
Comp: $745.15k

Ms. Theresa Marie Heggie (Age 62)
Chief Operating Officer
Comp: $29.08k

Dr. Gerard Platenburg (Age 58)
Co-Founder & Chief Scientific Officer

Ms. Smital Shah M.B.A. (Age 46)
Chief Bus. & Financial Officer

Mr. Rene K. Beukema (Age 58)
Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board

Ms. Sarah Cue Kiely
VP of Investor Relations & Corp. Communications

Ms. Sheila Sponselee
VP of HR

Mr. Bart Klein
Sr. VP of Intellectual Property

Mr. Aniz Girach M.D. (Age 55)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.
What is ProQR Therapeutics' stock price forecast for 2022?: 8 brokerages have issued 1-year target prices for ProQR Therapeutics' shares. Their PRQR share price forecasts range from $2.00 to $17.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 491.6% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.
How have PRQR shares performed in 2022?: ProQR Therapeutics' stock was trading at $8.01 at the start of the year. Since then, PRQR stock has decreased by 89.4% and is now trading at $0.8451.
View the best growth stocks for 2022 here.
When is ProQR Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PRQR earnings forecast.
How were ProQR Therapeutics' earnings last quarter?: ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The biopharmaceutical company had revenue of $1.09 million for the quarter, compared to analysts' expectations of $1.21 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 57.34% and a negative net margin of 1,859.05%.

What other stocks do shareholders of ProQR Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).
What is ProQR Therapeutics' stock symbol?: ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."
How do I buy shares of ProQR Therapeutics?: Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ProQR Therapeutics' stock price today?: One share of PRQR stock can currently be purchased for approximately $0.85.
How much money does ProQR Therapeutics make?: ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $60.25 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72,900,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
How many employees does ProQR Therapeutics have?: The company employs 1,504 workers across the globe.
How can I contact ProQR Therapeutics?: ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ProQR Therapeutics - PRQR Stock Forecast, Price & News

ProQR Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows